Amicus Therapeutics, Inc. (OQ:FOLD)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for FOLD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 21st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Common Stock S - Open market or private sale -20,000 $10.83
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 20,000 $5.13
Feb 14/20 Feb 12/20 Clark David Michael Direct Ownership Common Stock S - Open market or private sale -7,107 $11.00
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -17,652  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -29,148  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,300  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock S - Open market or private sale -63,356 $11.01
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 17,652 $5.13
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 29,148 $6.10
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for FOLD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET February 21st, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -20,000  
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Common Stock S - Open market or private sale -20,000 $10.83
Feb 20/20 Feb 18/20 Crowley John F Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 20,000 $5.13
Feb 14/20 Feb 12/20 Clark David Michael Direct Ownership Common Stock S - Open market or private sale -7,107 $11.00
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -17,652  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -29,148  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Stock Options (right to buy) M - Exercise or conversion exempt under rule 16b-3 -6,300  
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock S - Open market or private sale -63,356 $11.01
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 17,652 $5.13
Feb 14/20 Feb 12/20 Do Hung Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 29,148 $6.10
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $FOLD

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Alnylam Pharmaceuticals (OQ:ALNY)
Vir Biotechnology (OQ:VIR)